Testosterone naturally declines as men age.
Drug companies have capitalized on this reality by manufacturing prescription testosterone replacement products, and sales of these treatments exceed $2 billion every year.
Despite the popularity of testosterone replacement products a study published in 2010 in the New England Journal of Medicine found that testosterone treatment increased the risk of cardiovascular events such as heart attack and stroke in older men.
Another study published in 2015 did not see any noteworthy advancement of vascular disease in patients using testosterone replacement therapy, but also did not perceive any benefit or improvement in the quality of life of patients who underwent testosterone replacement therapy.
AndroGel is currently one of the leading testosterone replacement treatments on the market, with sales of $675 million in 2016, according to Reuters.